These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20645028)

  • 1. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.
    Ličar A; Cerkovnik P; Novaković S
    Med Oncol; 2011 Dec; 28(4):1048-53. PubMed ID: 20645028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.
    Marchoudi N; Amrani Hassani Joutei H; Jouali F; Fekkak J; Rhaissi H
    Pathol Biol (Paris); 2013 Dec; 61(6):273-6. PubMed ID: 23849768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
    BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
    Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
    Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
    Roa I; Game A; Bizama C; Schalper K
    Rev Med Chil; 2014 Jan; 142(1):55-60. PubMed ID: 24861115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
    Bagadi SB; Sanghvi M; Nair SB; Das BR
    Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
    Licar A; Cerkovnik P; Ocvirk J; Novakovic S
    Int J Oncol; 2010 May; 36(5):1137-44. PubMed ID: 20372787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer.
    Galbiati S; Damin F; Pinzani P; Mancini I; Vinci S; Chiari M; Orlando C; Cremonesi L; Ferrari M
    PLoS One; 2013; 8(3):e59939. PubMed ID: 23536897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.